GERN Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals has a net margin of -50.09% compared to Geron's net margin of -53.36%. Geron's return on equity of -46.58% beat Madrigal Pharmaceuticals's return on equity of -49.57%.

Geron has a consensus price target of $3.69, signalling upside risk potential of 154.31%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $423.14 which suggests that it could grow by 58.15%. Given that Geron has higher upside potential than Madrigal Pharmaceuticals, analysts believe Geron is more attractive than Madrigal Pharmaceuticals.

Geron has a beta of 0.765, which suggesting that the stock is 23.471% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Geron's net income of -$19.8M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Geron's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 8.25x versus 18.37x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -50.09% compared to Geron's net margin of -60.08%. Geron's return on equity of -46.58% beat Sarepta Therapeutics's return on equity of -20.94%.

Geron has a consensus price target of $3.69, signalling upside risk potential of 154.31%. On the other hand Sarepta Therapeutics has an analysts' consensus of $89.96 which suggests that it could grow by 137.36%. Given that Geron has higher upside potential than Sarepta Therapeutics, analysts believe Geron is more attractive than Sarepta Therapeutics.

Geron has a beta of 0.765, which suggesting that the stock is 23.471% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Geron's net income of -$19.8M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Geron's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 8.25x versus 1.89x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Alpha Teknova has a net margin of -50.09% compared to Geron's net margin of -47.42%. Geron's return on equity of -46.58% beat Alpha Teknova's return on equity of -28.37%.

Geron has a consensus price target of $3.69, signalling upside risk potential of 154.31%. On the other hand Alpha Teknova has an analysts' consensus of $11.00 which suggests that it could grow by 84.26%. Given that Geron has higher upside potential than Alpha Teknova, analysts believe Geron is more attractive than Alpha Teknova.

Geron has a beta of 0.765, which suggesting that the stock is 23.471% less volatile than S&P 500. In comparison Alpha Teknova has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Alpha Teknova pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are larger than Alpha Teknova quarterly revenues of $9.8M. Geron's net income of -$19.8M is lower than Alpha Teknova's net income of -$4.6M. Notably, Geron's price-to-earnings ratio is -- while Alpha Teknova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 8.25x versus 7.79x for Alpha Teknova. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -50.09% compared to Geron's net margin of -15.19%. Geron's return on equity of -46.58% beat Zevra Therapeutics's return on equity of -198.46%.

Geron has a consensus price target of $3.69, signalling upside risk potential of 154.31%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.71 which suggests that it could grow by 151.03%. Given that Geron has higher upside potential than Zevra Therapeutics, analysts believe Geron is more attractive than Zevra Therapeutics.

Geron has a beta of 0.765, which suggesting that the stock is 23.471% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.870, suggesting its more volatile than the S&P 500 by 87.041%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are larger than Zevra Therapeutics quarterly revenues of $20.4M. Geron's net income of -$19.8M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Geron's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 8.25x versus 10.51x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.